Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2020.575047 http://scihub22266oqcxt.onion/10.3389/fimmu.2020.575047 33123154!7573491!33123154     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2020 ; 11 (ä): 575047 Nephropedia Template TP {{tp|p=33123154|t=2020. Increased Plasma Heparanase Activity in COVID-19 Patients |pdf=|usr=}}{{33123154}} gab.com Text Increased Plasma Heparanase Activity in COVID-19 Patients JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33123154 #FOAvip Reports suggest a role of endothelial dysfunction and loss of endothelial barrier function in COVID-19. It is well established that the endothelial glycocalyx-degrading enzyme heparanase contributes to vascular leakage and inflammation. Low molecular weight heparins (LMWH) serve as an inhibitor of heparanase. We hypothesize that heparanase contributes to the pathogenesis of COVID-19, and that heparanase may be inhibited by LMWH. To test this hypothesis, heparanase activity and heparan sulfate levels were measured in plasma of healthy controls (n = 10) and COVID-19 patients (n = 48). Plasma heparanase activity and heparan sulfate levels were significantly elevated in COVID-19 patients. Heparanase activity was associated with disease severity including the need for intensive care, lactate dehydrogenase levels, and creatinine levels. Use of prophylactic LMWH in non-ICU patients was associated with a reduced heparanase activity. Since there is no other clinically applied heparanase inhibitor currently available, therapeutic treatment of COVID-19 patients with low molecular weight heparins should be explored. Twit Text FOAVip Increased Plasma Heparanase Activity in COVID-19 Patients ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33123154 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33123154 #FOAvip English Wikipedia <ref>{{Cite pmid|33123154}}</ref> Increased Plasma Heparanase Activity in COVID-19 Patients #MMPMID33123154 Buijsers B; Yanginlar C; de Nooijer A; Grondman I; Maciej-Hulme ML; Jonkman I; Janssen NAF; Rother N; de Graaf M; Pickkers P; Kox M; Joosten LAB; Nijenhuis T; Netea MG; Hilbrands L; van de Veerdonk FL; Duivenvoorden R; de Mast Q; van der Vlag J Front Immunol 2020[]; 11 (ä): 575047 PMID33123154show ga Reports suggest a role of endothelial dysfunction and loss of endothelial barrier function in COVID-19. It is well established that the endothelial glycocalyx-degrading enzyme heparanase contributes to vascular leakage and inflammation. Low molecular weight heparins (LMWH) serve as an inhibitor of heparanase. We hypothesize that heparanase contributes to the pathogenesis of COVID-19, and that heparanase may be inhibited by LMWH. To test this hypothesis, heparanase activity and heparan sulfate levels were measured in plasma of healthy controls (n = 10) and COVID-19 patients (n = 48). Plasma heparanase activity and heparan sulfate levels were significantly elevated in COVID-19 patients. Heparanase activity was associated with disease severity including the need for intensive care, lactate dehydrogenase levels, and creatinine levels. Use of prophylactic LMWH in non-ICU patients was associated with a reduced heparanase activity. Since there is no other clinically applied heparanase inhibitor currently available, therapeutic treatment of COVID-19 patients with low molecular weight heparins should be explored. |Aged[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/immunology/pathology[MESH] |Creatinine/blood[MESH] |Critical Care[MESH] |Cross-Sectional Studies[MESH] |Endothelium/*pathology[MESH] |Female[MESH] |Glucuronidase/*antagonists & inhibitors/*blood/metabolism[MESH] |Heparin Antagonists/*therapeutic use[MESH] |Heparin, Low-Molecular-Weight/*therapeutic use[MESH] |Heparitin Sulfate/blood[MESH] |Humans[MESH] |Interleukin-6/blood[MESH] |L-Lactate Dehydrogenase/blood[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/immunology/pathology[MESH] |SARS-CoV-2[MESH]Increased Plasma Heparanase Activity in COVID-19 Patients (epmc).pdf DeepDyve Pubget Overpricing